| Authors: |
Kopruszinski CM; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA., Linley JE; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Thornton P; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Walker AS; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Newton P; Discovery Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Podichetty S; Discovery Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Ruparel RH; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA., Moreira de Souza LH; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA., Navratilova E; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.; Department of Neurology, Mayo Clinic, Phoenix, AZ 85054, USA., Meno-Tetang G; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Gurrell I; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Dodick DW; Department of Neurology, Mayo Clinic, Phoenix, AZ 85054, USA.; Atria Academy of Science and Medicine, New York, NY 10022, USA., Dobson C; Discovery Sciences, AstraZeneca, Cambridge, CB2 0AA, UK., Chessell T; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK., Porreca F; Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.; Department of Neurology, Mayo Clinic, Phoenix, AZ 85054, USA., Chessell I; Neuroscience, BioPharmaceutical R&D, AstraZeneca, Cambridge, CB2 0AA, UK. |
